DaVita (NYSE:DVA – Free Report) had its target price trimmed by Barclays from $224.00 to $216.00 in a report released on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.
A number of other analysts have also commented on DVA. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial cut their price target on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Oppenheimer set a $220.00 price target on DaVita in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 price objective on shares of DaVita in a research note on Wednesday, August 5th. Finally, TD Cowen upped their price objective on DaVita from $220.00 to $228.00 and gave the company a “buy” rating in a report on Monday. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.86.
Read Our Latest Analysis on DVA
DaVita Stock Up 5.7%
DaVita stock opened at $192.59 on Monday. The business’s 50-day simple moving average is $181.98 and its 200 day simple moving average is $177.72. The stock has a market cap of $12.11 billion, a price-to-earnings ratio of 14.18, a P/E/G ratio of 0.46 and a beta of 0.87. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49.
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.57 by $0.25. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The firm had revenue of $3.58 billion during the quarter, compared to analysts’ expectations of $3.52 billion. During the same period in the previous year, the business posted $2.51 EPS. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, sell-side analysts expect that DaVita will post 14.66 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fifth Third Bancorp lifted its holdings in DaVita by 831.4% during the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares during the last quarter. Berkshire Hathaway Inc acquired a new position in DaVita in the 2nd quarter valued at $6,425,269,000. Wellington Management Group LLP increased its position in DaVita by 305.1% during the 2nd quarter. Wellington Management Group LLP now owns 9,610 shares of the company’s stock worth $2,138,000 after buying an additional 7,238 shares during the period. Assenagon Asset Management S.A. increased its position in DaVita by 30.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock worth $9,963,000 after buying an additional 10,477 shares during the period. Finally, Wealthfront Advisers LLC acquired a new stake in shares of DaVita during the second quarter worth $2,357,000. 90.12% of the stock is currently owned by institutional investors.
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.
DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.
The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.
Featured Stories
- Five stocks we like better than DaVita
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
